News update from Physiomics December 2024

17 Dec

News update from Physiomics December 2024

in Blog

Leading mathematical modelling company, supporting oncology drug development.

A Transformative Year at Physiomics – Innovation, Collaboration and Success

As 2024 draws to a close, we’re taking a moment to look back on an incredible year at Physiomics plc. From strengthening collaborations with global leaders to expanding our capabilities and welcoming fantastic new talent to the team, it’s been a year of exciting progress, working alongside leaders in drug development to help bring life-changing therapies to patients. Here’s a glimpse at some of the highlights that made 2024 so memorable.

Leadership Transition

2024 kicked off with a major milestone for Physiomics as Dr Peter Sargent took on the role of CEO. Pete’s leadership has brought a renewed focus on applying Physiomics’ expertise to address the real-world challenges faced in drug development, culminating in the launch of our new Biostatistics service and expanded capabilities in Data Science to drive even greater value for our clients. As we look ahead, we’re excited to build on this momentum to support clients across a broader range of drug development needs and continue to deliver impactful insights.

Collaborating with Industry Leaders

This year, we had the pleasure of deepening our existing partnerships and building new ones.

- We teamed up again with Numab Therapeutics AG to optimise dosing and scheduling for an oncology asset, helping it take a significant step forward as it enters the clinic, and to guide the Target Candidate Profile (TCP) for one of their key pre-clinical assets.
- We welcomed a new collaboration with a leading UK-based biotech using our Virtual Tumour™ technology to guide Phase 1b/2 dosing regimens.
- Additionally, we expanded our work with a long-standing pharma client on multiple projects, updating models focused on DNA damage repair to support clinical dose optimisation and incorporating an Antibody-Drug Conjugate (ADC) into our Virtual Tumour™ platform.
- We also collaborated with Cancer Research UK (CRUK) on an exciting new project to develop a PKPD model for FIH dose selection.

Expanding Our Expertise

In October, we officially launched our Biostatistics offering, alongside expanding our Data Science and Bioinformatics services. These additions allow us to provide even more comprehensive, data-driven insights, helping our clients optimise every stage of drug development – from trial design, execution and reporting to refining therapeutic strategies.

Welcoming New Talent

In November, we welcomed Dr. Mark Davies as our new Head of Quantitative Pharmacology and Data Science. Mark’s expertise enhances our ability to deliver critical insights, while his creative approach to solving complex drug development challenges – including the use of real-world data (RWD) – brings new opportunities for advancing innovation.

Engaging with the Scientific Community

This year, we’ve been excited to participate in key industry events, to share our work with thought leaders in drug development and discuss the important role of modelling, biostatistics and data science in driving advancements across various therapies and disease areas:

Industry Insight

- In October, we presented at ENA 2024, where we highlighted key findings from our PARTNER trial, showcasing the capabilities of our precision dosing tool. Check out our poster here: https://www.physiomics.co.uk/portfolio-item/data-analysis-and-model-evaluation-of-chemotherapy-induced-neutropenia-results-from-the-partner-trial/
- We had great discussions with industry leaders at partnering events such as BioForward, BioEurope, and BIO International throughout the year.
- We also attended several major industry events, including the World ADC Event (March), Oxford Global Immuno UK Event (April), and PKUK 2024 (December).

Collaborative Research Highlights

In February, we supported The University of Sheffield in securing a grant funded by Yorkshire Cancer Research for an innovative project developing insect cancer models to improve metastasis prediction in oncology. Physiomics will explore how these models translate to existing animal models and humans to accelerate drug screening.

In June, we expanded our collaboration with DoseMe, integrating our personalised dosing tools into their precision dosing platform. This partnership focuses on improving GCSF dosing strategies to better manage chemotherapy-induced neutropenia, with the ultimate goal of enhancing patient outcomes while reducing costs.

Looking Ahead

2024 has been a year of great progress and collaboration. As we move into 2025, we’re excited to keep building on this momentum. Whether it’s through bespoke PKPD modelling, the continued evolution of our Virtual Tumour™ platform, or the expansion of our biostatistics capabilities, we’re committed to delivering solutions that not only accelerate but also de-risk the development of life-changing therapies.

Peter Sargent, CEO, shares: “This year has been an exciting chapter for Physiomics. As we look to 2025, we’re focussed on expanding our reach further, to improve outcomes at every stage of drug development and support delivery of effective therapies to the right patients. With our incredible team and the relationships that we’re building, we’re excited for what’s to come.”

A huge thank you to our clients, collaborators, and team members for being part of this journey. We’re looking forward to all that we’ll accomplish together in the year ahead.

GET IN TOUCH